GlassScriptPhysician profile
Andrew P Pitman
NPI 1679599948
$2,821.92
in general payments reported to CMS, 2019-2025
24 companies · $221 in 2025
The $221 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $789 · 2020: $319 · 2021: $359 · 2022: $438 · 2023: $421 · 2024: $276 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $918.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $918.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,117.97 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $368.25 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $244.07 | 2019-2023 | Stiolto Respimat, Spiriva Respimat |
| Abbvie INC. | $159.14 | 2022-2025 | |
| Insmed, INC. | $145.80 | 2019 | |
| Innovation Technologies INC | $124.99 | 2023 | Irrisept |
| Paratek Pharmaceuticals, INC. | $122.90 | 2020 | |
| Baxter Healthcare | $88.85 | 2020-2024 | Hillrom - Life 2000 Ventilation System |
| Regeneron Pharmaceuticals, INC. | $58.61 | 2025 | Dupixent |
| Genentech USA, INC. | $54.45 | 2019-2021 | |
| Mirati Therapeutics, INC. | $37.94 | 2023-2024 | Krazati |
| Takeda Pharmaceuticals U.S.A., INC. | $32.24 | 2022 | |
| Grifols USA, LLC | $31.90 | 2025 | Prolastin-C Liquid |
| Sunovion Pharmaceuticals INC. | $30.63 | 2019 | |
| Merck Sharp & Dohme LLC | $29.84 | 2025 | Keytruda |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $24.31 | 2024 | Rybrevant |
| Electromed, INC. | $22.50 | 2024 | Smartvest |
| Circassia INC. | $21.19 | 2019 | |
| Phadia US INC. | $20.73 | 2019 | |
| Pfizer INC. | $19.69 | 2022 | |
| Daiichi Sankyo INC. | $19.27 | 2025 | Enhertu |
| Janssen Pharmaceuticals, INC | $17.19 | 2019 | |
| Resmed Corp | $15.30 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Pitman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.